The first oral pill for obstructive sleep apnea could be around the corner after company Apnimed reported positive results ...

Pharmaceutical company Apnimed says it's getting positive results from the clinical trials for an oral pill that could treat ...

The new pill, called AD109, is a combination of atomoxetine and aroxybutynin, two drugs that tell your brain to keep the ...

Apnimed has scored another phase 3 knockout. The Massachusetts biotech’s daily pill for obstructive sleep apnea reduced the ...

Sleep apnea is a condition where breathing repeatedly stops or reduces during sleep, often due to airway obstruction. It ...

After announcing a $20 million funding round in June, the startup has set its sights on growing its customer-facing workforce ...

Obstructive sleep apnea is still largely undiagnosed and untreated. In a growing marketplace of solutions, can negative ...

This can lead to delays in diagnosis as sleep apnea in women can be mistaken for anxiety, depression and menopause. As the signs are more subtle, research suggests as many as 90% of women who have ...

Apnimed, Inc., a pharmaceutical company advancing an industry-leading pipeline of first-in-class oral therapies that address the root causes of obstructive sleep apnea (OSA) and other sleep-related ...

A new study found active-duty service members with sleep apnea face a greater risk of PTSD or a traumatic brain injury, ...

A retrospective study shows sleep apnea can increase the risk for retinal vein occlusion in both men and women and is ...

If left untreated, obstructive sleep apnea raises the risk of hypertension, heart disease, type 2 diabetes, depression and even an early death, according to the American Academy of Sleep Medicine.